Compare · NBIX vs TCBP
NBIX vs TCBP
Side-by-side comparison of Neurocrine Biosciences Inc. (NBIX) and TC BioPharm (Holdings) plc (TCBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NBIX and TCBP operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- NBIX carries a market cap of $16.73B.
- NBIX has hit the wire 11 times in the past 4 weeks while TCBP has been quiet.
- NBIX has more recent analyst coverage (25 ratings vs 0 for TCBP).
- Company
- Neurocrine Biosciences Inc.
- TC BioPharm (Holdings) plc
- Price
- -
- -
- Market cap
- $16.73B
- -
- 1M return
- +21.71%
- -
- 1Y return
- +15.02%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1996
- 2022
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 0
Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
TC BioPharm (Holdings) plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Latest NBIX
- Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
- Chief Medical Officer Roberts Eiry was granted 8,314 stock options and was granted 1,506 restricted stock units (SEC Form 4)
- Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
- Director Morrow George J exercised 15,000 shares at a strike of $53.64 and sold $2,335,982 worth of shares (15,000 units at $155.73) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Gano Kyle converted options into 614 shares and covered exercise/tax liability with 332 shares, increasing direct ownership by 0.18% to 155,010 units (SEC Form 4) to satisfy withholding obligation
- Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- SEC Form 10-Q filed by Neurocrine Biosciences Inc.
- Neurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
Latest TCBP
- TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
- SEC Form 6-K filed by TC BioPharm (Holdings) plc
- TCBP Announces Transition from Nasdaq to OTC Markets
- TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
- TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
- TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
- TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
- SEC Form 6-K filed by TC BioPharm (Holdings) plc
- TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
- TCBP to Implement ADS Ratio Change